Skip to main content
Year archive

Cantargia — 2021 filings

All 77 regulatory filings released by Cantargia (CANTA) in 2021, sourced directly from the official regulator.

77 Filings
2021 Period
2021 filings (77)
Filing Released Lang
Cantargia rapporterar uppdaterade lovande överlevnadsdata från CANFOUR-studien med nadunolimab och cellgifter i bukspottkörtelcancer
Earnings Release FY 2021
2021-12-29 Swedish
Cantargia reports updated encouraging survival data from CANFOUR trial with nadunolimab and chemotherapy in pancreatic cancer
Legal Proceedings Report
2021-12-29 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-12-22 English
Cantargia reports positive results for CAN10 antibody in preclinical systemic sclerosis model
Regulatory Filings
2021-12-13 English
Cantargia rapporterar positiva resultat för antikroppen CAN10 i en preklinisk modell av systemisk skleros
Regulatory Filings
2021-12-13 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-12-09 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-12-03 English
Cantargia reports opposition against recently granted European patent
Legal Proceedings Report
2021-12-01 English
Cantargia rapporterar om opposition mot nyligen godkänt europeiskt patent
Legal Proceedings Report
2021-12-01 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report 9M 2021
2021-11-11 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report 9M 2021
2021-11-11 English
Cantargia rapporterar framsteg i produktionsutvecklingen och uppdaterar kring förberedelserna av klinisk studie för CAN10
Regulatory Filings
2021-11-08 Swedish
Cantargia reports progress in manufacturing process development and provides update on clinical trial preparations for CAN10
Regulatory Filings
2021-11-08 English
Valberedning utsedd inför årsstämman 2022
Board/Management Information
2021-10-29 Swedish
Nomination Committee appointed ahead of 2022 Annual General Meeting
Board/Management Information
2021-10-29 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-10-26 English
Cantargia rapporterar behandling av första patienten i kliniska studien CESTAFOUR
Legal Proceedings Report
2021-10-22 Swedish
Cantargia reports treatment of first patient in CESTAFOUR clinical trial
Regulatory Filings
2021-10-22 English
Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer
Regulatory Filings
2021-10-14 English
Cantargia erhåller positivt utlåtande från EMA om särläkemedelsstatus för nadunolimab vid behandling av bukspottkörtelcancer
Regulatory Filings
2021-10-14 Swedish
Cantargias omfattande patentskydd för målstyrda cancerterapier mot IL1RAP kvarstår efter avslutad oppositionsprocess
Regulatory Filings
2021-09-30 Swedish
Cantargia’s extensive patent protection for IL1RAP-targeting cancer therapy remains in force after concluded opposition
Regulatory Filings
2021-09-30 English
Cantargia receives regulatory approval to start TRIFOUR study in triple negative breast cancer
Legal Proceedings Report
2021-09-29 English
Cantargia erhåller regulatoriskt godkännande för start av TRIFOUR-studien i trippelnegativ bröstcancer
Regulatory Filings
2021-09-29 Swedish
Cantargia: FDA grants Orphan Drug Designation to nadunolimab for treatment of pancreatic cancer
Regulatory Filings
2021-09-22 English
Cantargia: FDA tilldelar särläkemedelsstatus (Orphan Drug Designation) till nadunolimab för behandling av bukspottkörtelcancer
Legal Proceedings Report
2021-09-22 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification
2021-09-16 English
Cantargia presenterar positiva interimsdata för kombinationsterapi med nadunolimab på ESMO-konferensen
Earnings Release H2 2021
2021-09-16 Swedish
Cantargia presents positive interim data for nadunolimab combination therapy at ESMO Congress
Earnings Release FY 2021
2021-09-16 English
Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress
Earnings Release FY 2021
2021-09-13 English
Cantargia: Nya positiva interimsdata för kombinationsterapi med nadunolimab i NSCLC har publicerats i ett vetenskapligt abstrakt inför årets ESMO-konferens
Regulatory Filings
2021-09-13 Swedish
Cantargia erhåller regulatoriskt godkännande att påbörja den kliniska studien CESTAFOUR med nadunolimab i kombination med cellgifter
Legal Proceedings Report
2021-09-10 Swedish
Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy
Legal Proceedings Report
2021-09-10 English
Cantargia completes patient recruitment to the phase IIa pancreatic cancer extension cohort in the CANFOUR study
Regulatory Filings
2021-09-10 English
Cantargia fullbordar patientrekryteringen till fas IIa extensionskohorten i pankreascancer inom CANFOUR-studien
Regulatory Filings
2021-09-10 Swedish
Cantargia expanderar utvecklingen av nadunolimab i icke-skivepitel-NSCLC
Regulatory Filings
2021-09-06 Swedish
Cantargia expands nadunolimab development in non-squamous NSCLC
Legal Proceedings Report
2021-09-06 English
Cantargia förstärker bolagets ledningsgrupp
Board/Management Information
2021-09-01 Swedish
Cantargia strengthens the company management team
Board/Management Information
2021-09-01 English
Cantargia reports preclinical data highlighting advantages of nadunolimab mechanism of action
Regulatory Filings
2021-08-30 English
Cantargia rapporterar prekliniska data som påvisar fördelarna med nadunolimabs verkningsmekanism
Regulatory Filings
2021-08-30 Swedish
Cantargia reports first patient treated in CAPAFOUR study investigating combination of nadunolimab with FOLFIRINOX in pancreatic cancer
Legal Proceedings Report
2021-08-26 English
Cantargia rapporterar behandling av första patienten i CAPAFOUR-studien som utvärderar kombination av nadunolimab och FOLFIRINOX i bukspottkörtelcancer
Regulatory Filings
2021-08-26 Swedish
Cantargia expands CIRIFOUR trial after successful completion of recruitment in the pembrolizumab combination arm
Legal Proceedings Report
2021-08-19 English
Cantargia expanderar CIRIFOUR-studien efter avslutad rekrytering till kombinationsarmen med pembrolizumab
Legal Proceedings Report
2021-08-19 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report H2 2021
2021-08-19 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report H2 2021
2021-08-19 English
Cantargia advances development of nadunolimab in triple negative breast cancer through submission of clinical protocol for TRIFOUR study
Regulatory Filings
2021-07-01 English
Cantargia tar nästa steg i utvecklingen av nadunolimab inom trippelnegativ bröstcancer genom inlämning av klinisk ansökan för TRIFOUR-studie
Legal Proceedings Report
2021-07-01 Swedish
Cantargia broadens the development of nadunolimab in three forms of cancer and submits application for the phase I/II clinical trial CESTAFOUR
Regulatory Filings
2021-06-29 English
Cantargia breddar utvecklingen av nadunolimab i tre cancerformer och ansöker om start av fas I/II kliniska studien CESTAFOUR
Regulatory Filings
2021-06-29 Swedish
Annual Report 2020
Annual Report FY 2020
2021-06-29 English
Cantargia receives regulatory approval to start clinical trial investigating nadunolimab and FOLFIRINOX in pancreatic cancer
Regulatory Filings
2021-06-08 English
Cantargia erhåller regulatoriskt godkännande att påbörja klinisk studie för utvärdering av nadunolimab och FOLFIRINOX i bukspottkörtelcancer
Regulatory Filings
2021-06-08 Swedish
Årsstämma i Cantargia AB (publ)
AGM Information
2021-05-26 Swedish
Annual General Meeting in Cantargia AB (publ)
AGM Information
2021-05-26 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-26 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Q1 2021
2021-05-26 English
Cantargia rapporterar positiva resultat från en pågående fas IIa klinisk studie i bukspottkörtelcancer med nadunolimab och cellgifter
Earnings Release FY 2021
2021-05-19 Swedish
Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy
Earnings Release FY 2021
2021-05-19 English
Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10
Earnings Release FY 2021
2021-05-10 English
Cantargia presenterar nya prekliniska data som visar att antikroppen CAN10 åstadkommer en unik förbättring av hjärtfunktion vid hjärtmuskelinflammation
Earnings Release FY 2021
2021-05-10 Swedish
Cantargia tar nästa steg i utvecklingen av antikroppen CAN04 med en ny klinisk studie i trippelnegativ bröstcancer
Legal Proceedings Report
2021-05-06 Swedish
Cantargia advance development of antibody CAN04 by a new clinical trial in triple negative breast cancer
Regulatory Filings
2021-05-06 English
Annual Report 2020
Annual Report FY 2020
2021-04-30 Swedish
Kallelse till årsstämma i Cantargia AB (publ)
AGM Information
2021-04-27 Swedish
Notice of annual general meeting in Cantargia AB (publ)
AGM Information
2021-04-27 English
Cantargia presenterar nya prekliniska resultat kring antikroppen CAN10 på IMMMUNOLOGY2021
Regulatory Filings
2021-04-26 Swedish
Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021
Regulatory Filings
2021-04-26 English
Cantargia reports positive preclinical safety and efficacy results in the CAN10 project
Earnings Release Q2 2021
2021-03-19 English
Cantargia rapporterar positiva prekliniska resultat kring säkerhet och effekt i CAN10-projektet
Earnings Release Q2 2021
2021-03-19 Swedish
Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer
Legal Proceedings Report
2021-03-10 Swedish
Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can
Regulatory Filings
2021-03-10 English
Earnings Release 2020
Earnings Release FY 2020
2021-02-25 Swedish
Annual Report 2020
Annual Report FY 2020
2021-02-25 English
Cantargia reports first patient treated in CANFOUR pancreatic cancer phase IIa extension cohort
Legal Proceedings Report
2021-02-10 English
Cantargia meddelar att första patienten med behandlats i fas IIa extensionsdel av CANFOUR-studien i bukspottkörtelcancer
Regulatory Filings
2021-02-10 Swedish